🚨🚨📣📣🏥🏥#HealthIsWealth TREATMENT TO REJUVENATE HUMAN CELLS #BinanceAlphaAlert
On June 9, 2026, the biotechnology company Life Biosciences for the first time administered to a human patient an experimental cellular reprogramming treatment aimed at reversing the aging of cells.$BTC
Treatment details: The technology: The treatment uses three specific proteins (Oct4, Sox2, KLF4), known as Yamanaka factors, to reset the cells’ epigenetic age without erasing their identity.
The medical target: The phase 1 clinical trial targets optic neuropathies (such as glaucoma) that destroy the neurons of the optic nerve and cause blindness. The eyes were chosen as the first area for testing because they are isolated organs with a lower risk of side effects.
Safety: To prevent the cells from going out of control (and to avoid cancer risks), the rejuvenation genes are controlled by a genetic switch that only activates when the patient takes a specific antibiotic (doxycycline).
On June 9, 2026, the biotechnology company Life Biosciences for the first time administered to a human patient an experimental cellular reprogramming treatment aimed at reversing the aging of cells.$BTC
Treatment details: The technology: The treatment uses three specific proteins (Oct4, Sox2, KLF4), known as Yamanaka factors, to reset the cells’ epigenetic age without erasing their identity.
The medical target: The phase 1 clinical trial targets optic neuropathies (such as glaucoma) that destroy the neurons of the optic nerve and cause blindness. The eyes were chosen as the first area for testing because they are isolated organs with a lower risk of side effects.
Safety: To prevent the cells from going out of control (and to avoid cancer risks), the rejuvenation genes are controlled by a genetic switch that only activates when the patient takes a specific antibiotic (doxycycline).